Across various cancers, like melanoma, colorectal cancer, and lung cancer, immune checkpoint inhibitors including anti-PD-1/PD-L1, anti-CTLA-4, and anti-Tim3, has significantly enhanced progression-free and overall survival rates. This evidence concerns the gene HAVCR2 and colorectal cancer.